The novel finding of this trial is that this DNA/PSA vaccine, given together with GM-CSF and IL-2 to patients with prostate cancer, is safe and in doses of 900 μg can induce PSA-specific immunity. This evidence concerns the gene CSF2 and prostate carcinoma.